Dr Reddys gets US FDA nod for Generic Navelbine injection

Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Generic Navelbine injection. The said injection is anti-cancer chemotherapy drug which used for Non-small cell lung cancer. Moreover, some healthcare providers may also give Navelbine for breast cancer, ovarian cancer, or Hodgkin’s disease.

Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.